Advances in Brief Modulation of Irinotecan-induced Diarrhea by Cotreatment with Neomycin in Cancer Patients


This study was designed to evaluate irinotecan (CPT11) disposition and pharmacodynamics in the presence and absence of the broad-spectrum antibiotic neomycin. Seven evaluable cancer patients experiencing diarrhea graded >2 after receiving CPT-11 alone (350 mg/m i.v. once every 3 weeks) received the same dose combined with oral neomycin at 1000 mg three… (More)


4 Figures and Tables